Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
29 Gennaio 2018 - 11:30PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D-9
(Rule
14d-101)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
Juno Therapeutics, Inc.
(Name of Subject Company)
Juno
Therapeutics, Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
48205A109
(CUSIP Number
of Class of Securities)
Bernard J. Cassidy
General Counsel & Corporate Secretary
400 Dexter Avenue North, Suite 1200
Seattle, Washington 98109
(206)
582-1600
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
Graham Robinson
Amr
Razzak
Skadden, Arps, Slate, Meagher & Flom LLP
500 Boylston Street, 23rd Floor
Boston, Massachusetts, 02116
(617)
573-4800
☒
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
This Schedule
14D-9
filing relates solely to preliminary communications
made before the commencement of a planned tender offer (the Offer) by Blue Magpie Corporation (Purchaser), a wholly owned subsidiary of Celgene Corporation (Celgene), for all of the outstanding shares of common
stock, par value $0.0001 per share, of Juno Therapeutics, Inc. (Juno), to be commenced pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018, by and among Celgene, Purchaser and Juno. If successful, the Offer
will be followed by a merger of Purchaser with and into Juno (the Merger).
|
|
|
Exhibit A:
E-mail
from Zachary Hale, Vice President & Deputy General Counsel of Juno Therapeutics, Inc., to Employees
|
|
|
|
Exhibit B: Transaction Impact on Equity Grants Attachment to E-mail from Zachary Hale, Vice President & Deputy General Counsel of Juno Therapeutics, Inc., to Employees
|
Grafico Azioni JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Storico
Da Giu 2023 a Giu 2024